CRISPR Therapeutics AG
CRSP
$43.34
-$2.19-4.81%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -138.43% | 32.23% | 36.09% | 58.56% | 76.37% |
| Total Depreciation and Amortization | -2.91% | -7.05% | -6.58% | -15.38% | -17.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.42% | -28.21% | -38.00% | -41.01% | -39.34% |
| Change in Net Operating Assets | 180.72% | -9.97% | 290.03% | -139.49% | -1,075.49% |
| Cash from Operations | 45.17% | 31.99% | 64.50% | 54.67% | 47.48% |
| Capital Expenditure | 79.93% | 84.02% | 77.24% | 71.35% | 74.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -172.52% | -257.49% | -167.99% | 11,850.35% | 273.44% |
| Cash from Investing | -174.87% | -266.72% | -174.92% | 704.38% | 244.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 430.53% | 1,252.95% | 771.32% | 989.14% | 62.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 429.78% | 1,251.17% | 770.15% | 989.14% | 62.38% |
| Foreign Exchange rate Adjustments | -128.77% | 0.00% | -94.67% | 242.86% | 191.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -151.58% | -1,133.23% | 169.76% | 205.26% | 124.73% |
